Congress Needs To Review “Authorized” Generics, Hatch And Waxman Agree
This article was originally published in The Pink Sheet Daily
Executive Summary
The legislature should consider how “authorized” generics affect the incentive for generic companies to pursue patent challenges, Sen. Hatch (R-Utah) tells a Drug & Device Dialogue audio conference. Rep. Waxman (D-Calif.) says Congress must “revisit” Waxman/Hatch if CMS does not address authorized generics through Medicaid “best price” reporting.
You may also be interested in...
FTC Should Study Competitive Impact Of "Authorized" Generics, Senators Say
Bipartisan group of senators requests investigation of the short- and long-term competitive impacts of "authorized" generics. Formal study request and remarks by one of the commissioners suggest the generic industry's arguments against the practice are gaining traction on Capitol Hill and at FTC.
FTC Should Study Competitive Impact Of "Authorized" Generics, Senators Say
Bipartisan group of senators requests investigation of the short- and long-term competitive impacts of "authorized" generics. Formal study request and remarks by one of the commissioners suggest the generic industry's arguments against the practice are gaining traction on Capitol Hill and at FTC.
CMS Lacks Authority To Include "Authorized" Generic In A Brand's "Best Price"
HHS Secretary Leavitt suggests the agency cannot dictate that the "best price" of an "authorized" generic be included in the Medicaid rebate calculation for the brand drug. The position appears to be a blow for the generic industry, which is seeking to change rebate reporting requirements for brand drugs with authorized generics.